



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad – 500 081, Telangana, INDIA.

Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com

CIN: L24110TG1991PLC012471

Dated September 24, 2024

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Press Release

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Mam,

We are herewith enclosing the press release given by the Company.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

For GRANULES INDIA LIMITED

**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**



Granules India Unveils 'Breast Health Express' Mobile Unit: A Leap in Cancer Screening for Underserved Communities

Hyderabad, 24th September 2024: Granules India Ltd, a leading pharmaceutical company based in Hyderabad, proudly unveiled its Mobile Cancer Screening Unit at AIG Hospitals. This initiative, spearheaded by the Granules Trust in partnership with Asian Medical Foundation, UC Breast Foundation and AIG Hospitals aims to enhance cancer detection and treatment in underserved communities.

The state-of-the-art mobile unit "Breast Health Express," brings advanced medical technology directly to communities in need. Equipped with cutting-edge mammography and ultrasound capabilities, as well as facilities for essential health checks such as haemoglobin, blood pressure, and glucose levels, this mobile clinic marks a major advancement in equitable and accessible healthcare. By offering these critical services and free medicine distribution, the initiative seeks to revolutionize cancer screening, with a particular emphasis on early breast cancer detection.

Mrs. Uma Chigurupati, Executive Director of Granules India Ltd and Chairperson of the Granules Trust, emphasized the company's long-term vision for community well-being, *"The launch of the Breast Health Express embodies Granules India's core philosophy of innovating beyond pharmaceuticals to make a direct impact on public health. This launch is a testament to our commitment to addressing critical healthcare gaps, particularly in rural areas where access is often limited. By bringing breast cancer screening services to underserved populations, we are not only addressing an urgent health need but also reaffirming our belief that healthcare should be accessible to all."*

Dr. D. Nageshwar Reddy, Chairman of AIG Hospitals, emphasized the significance of the partnership, *"The collaboration between Granules Trust, Asian Medical Foundation, UC Breast Foundation and AIG Hospitals stands as a remarkable example of how private sector partnerships can effectively address critical healthcare challenges. The Breast Health Express will play a crucial role in extending vital screening services to remote communities, ensuring that essential cancer detection reaches those who need it most."*

Dr. Pragnya Chigurupati, Consultant Breast Oncologist at AIG and Founder of UC Breast Foundation, highlighted the transformative impact of the initiative *" Beyond screenings, Breast Health Express will raise awareness about breast health and empower women with the knowledge of regular self-examinations. Through this initiative and the ongoing efforts of the UC Breast Foundation, we aim to promote early detection, while also providing financial assistance to women in need of critical treatments, such as surgery, chemotherapy, and radiation therapy."*

Timed to coincide with Breast Cancer Awareness Month in October, the Breast Health Express aligns seamlessly with the global focus on breast cancer prevention and early detection. The mobile unit is set to commence operations in and around Hyderabad, with plans to expand to additional districts of Telangana in the coming months.

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast-growing Indian pharmaceutical company headquartered in Hyderabad with best-in-class facilities and a commitment to operational excellence, quality, and customer service. Amongst the few pharmaceutical companies in the world to be present across the manufacturing of the entire pharmaceutical value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs), Granules products are distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US and UK. The Company has 10 manufacturing facilities out of which 8 are located in India and 2 are in the USA and has regulatory approvals from the US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

For more information about Granules India Ltd and its initiatives, please visit www.granulesindia.com or contact:

Media Contact:

Priyanka Chawla
Manager- Corporate Communications
priyanka.chawla@granulesindia.com

Investors Contact:

Chaitanya Tummala
Company Secretary
040-69043614
chaitanya.tummala@granulesindia.com